Filing Flows › Companies › Immunome › Report card
Immunome earnings report card
Every report on file against what analysts and the company itself expected, and what the stock did
Beat rate0 of 3 reports beat the EPS estimate
Immunome (IMNM) beat the analysts' EPS estimate in 0 of its last 3 reports (0%), by -27.1% on average. Next report: Nov 10, 2026, analysts expect EPS −$0.60.
Beat rate0% of 3
Average surprise-27.1%
Next reportNov 10, 2026
Report by report
| Quarter | Reported | EPS est. | EPS reported | Surprise |
|---|---|---|---|---|
| Q to Jun 2026 | Aug 11, 2026 | −$0.50 | −$0.65 | -28.8% |
| Q to Dec 2025 | Mar 3, 2026 | −$0.57 | −$0.76 | -32.8% |
| Q to Sep 2025 | Nov 6, 2025 | −$0.54 | −$0.65 | -19.6% |
Estimates and reported EPS are the Street's adjusted figures. No daily prices are on file for these report days, so the stock's moves are not shown.
Charts
The next report: what to expect → Immunome: every quarter →
Read automatically from SEC filings, earnings releases and public estimates; errors are possible. Not investment advice.